Gilead Sciences (GILD) : Boston Common Asset Management reduced its stake in Gilead Sciences by 2.33% during the most recent quarter end. The investment management company now holds a total of 98,322 shares of Gilead Sciences which is valued at $8,520,585 after selling 2,345 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.Gilead Sciences makes up approximately 1.23% of Boston Common Asset Management’s portfolio.
Other Hedge Funds, Including , Murphy Capital Management Inc reduced its stake in GILD by selling 3,737 shares or 22.69% in the most recent quarter. The Hedge Fund company now holds 12,731 shares of GILD which is valued at $1,103,268. Gilead Sciences makes up approx 0.17% of Murphy Capital Management Inc’s portfolio. Trellus Management Company sold out all of its stake in GILD during the most recent quarter. The investment firm sold 5,000 shares of GILD which is valued $433,300.Btr Capital Management Inc boosted its stake in GILD in the latest quarter, The investment management firm added 2,235 additional shares and now holds a total of 85,037 shares of Gilead Sciences which is valued at $7,392,266. Gilead Sciences makes up approx 1.64% of Btr Capital Management Inc’s portfolio.Lau Associates reduced its stake in GILD by selling 800 shares or 2.72% in the most recent quarter. The Hedge Fund company now holds 28,600 shares of GILD which is valued at $2,475,330. Gilead Sciences makes up approx 2.57% of Lau Associates’s portfolio.Ct Financial Advisors reduced its stake in GILD by selling 400 shares or 40.0% in the most recent quarter. The Hedge Fund company now holds 600 shares of GILD which is valued at $51,930. Gilead Sciences makes up approx 0.03% of Ct Financial Advisors’s portfolio.
Gilead Sciences opened for trading at $85.46 and hit $87.12 on the upside on Wednesday, eventually ending the session at $86.66, with a gain of 1.43% or 1.22 points. The heightened volatility saw the trading volume jump to 90,55,877 shares. Company has a market cap of $115,416 M.
On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.